Inhibition of ATP-sensitive potassium channels by haloperidol

British Journal of Pharmacology

Volumn 143, Issue 8, 2004, Pages 960-967

  Yang, Shi Bing ^a   Proks, Peter ^b   Ashcroft, Frances M ^b   Rupnik, Marjan ^a  

^a EUROPEAN NEUROSCIENCE INSTITUTE   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ATP sensitive potassium channel; D2 receptor; Diabetes mellitus; Haloperidol; K ATP channel; Pancreatic cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; COMPLEMENTARY DNA; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; POTASSIUM CHANNEL; POTASSIUM ION;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BINDING SITE; DRUG EFFECT; EMBRYO; HUMAN; HUMAN CELL; KIDNEY CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; MALE; MICE; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 11244343978     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706017     Document Type: Article

References (45)

1. ATP channels. Physiol. Rev., 78, 227-245.
2. AGUILAR-BRYAN, L., NICHOLS, C.G., WECHSLER, S.W., CLEMENT IV, J.P., BOYD III, A.E., GONZALEZ, G., HERRERA-SOSA, H., NGUY, K., BRYAN, J. & NELSON, D.A. (1995). Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science, 268, 423-426.
3. + currents in acutely isolated rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci., 43, 1257-1261.
4. + channels and insulin secretion: their role in health and disease. Diabetologia, 42, 903-919.
5. ASHCROFT, F.M. & RORSMAN, P. (1989). Electrophysiology of the pancreatic beta-cell. Prog. Biophys. Mol. Biol., 54, 87-143.
6. + channels: a link between β-cell metabolism and insulin secretion Biochem. Soc. Trans., 18, 109-111.
7. BAPTISTA, T. (1999). Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta. Psychiat. Scand., 100, 3-16.
8. BAPTISTA, T., KIN, N.M., BEAULIEU, S. & DE BAPTISTA, E.A. (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry, 35, 205-219.
9. BOND, C.T., ÄMMÄLÄ, C., ASHFIELD, R., BLAIR, T.A., GRIBBLE, F., KHAN, R.N., LEE, K., PROKS, P., ROWE, I.C.M., SAKURA, H., ASHFORD, M.J., ADELMAN, J.P. & ASHCROFT, F.M. (1995). Cloning and functional expression of the cDNA encoding an inwardly-rectifying potassium channel expressed in pancreatic beta-cells and in the brain. FEBS Lett., 367, 61-66.
10. BUSE, J.B., CAVAZZONI, P., HORNBUCKLE, K., HUTCHINS, D., BREIER A., & JOVANOVIC, L. (2003). A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. Epidemiol., 56, 164-170.
11. CARMELIET, E. (1999). Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol. Rev., 79, 917-1017.
12. + channels and cellular actions of morphine in periaqueductal gray slices of neonatal and adult rats. J. Pharmacol. Exp. Ther., 298, 493-500.
13. EL-DENSHARY, E.E., ISMAIL, N.A., GAGERMAN, E., SEHLIN, J. & TALJEDAL, I.B. (1982). Bromocriptine and insulin secretion. Biosci. Rep., 2, 115-116.
14. FROEMMING, J.S., LAM, Y.W., JANN, M.W. & DAVIS, C.M. (1989). Pharmacokinetics of haloperidol. Clin. Pharmacokinet., 17, 396-423.
15. GALIZZI, J.P., FOSSET, M., ROMEY, G., LADURON, P. & LAZDUNSKI, M. (1986). Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc. Natl. Acad. Sci. U.S.A., 83, 7513-7517.
16. GESSNER, G. & HEINEMANN, S.H. (2003). Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br. J. Pharmacol., 138, 161-171.
17. GÖPEL, S., KANNO, T., BARG, S., GALVANOVSKIS, J. & RORSMAN, P. (1999). Voltage-gated and resting membrane currents recorded from β-cells in intact mouse pancreatic islets. J. Physiol., 521, 717-728.
18. + channels. J. Physiol., 528, 509-520.
19. GRIBBLE, F.M., WILLIAMS, L., SIMPSON, A.K. & REIMANN, F. (2003). A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes, 52, 1147-1154.
20. HÄGG, S., JOELSSON, L., MJORNDAL, T., SPIGSET, O., OJA, G. & DAHLQVIST, R. (1998). Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J. Clin. Psychiatry, 59, 294-299.
21. HERMANSEN, K. (1978). Haloperidol, a dopaminergic antagonist: somatostatin-like inhibition of glucagon and insulin release from the isolated, perfused canine pancreas. Diabetologia, 15, 343-347.
22. INAGAKI, N., TSUURA, Y., NAMBA, N., MASUDA, K., GONOI, T., HORIE, M., SEINO, Y., MIZUTA, M. & SEINO, S. (1995). Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J. Biol. Chem., 270, 5691-5694.
23. + channel by the antidepressant drug amitriptyline. Br. J. Pharmacol., 129, 1474-1480.
24. KANNO, T., GOPEL, S.O., RORSMAN, P. & WAKUI, M. (2002). Cellular function in multicellular system for hormone-secretion: electrophysiological aspect of studies on alpha-, beta- and delta-cells of the pancreatic islet. Neurosci. Res., 42, 79-90.
25. KAPUR, S. & REMINGTON, G. (2001). Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med., 52, 503-517.
26. + (GIRK) channels expressed in xenopus oocytes. Br. J. Pharmacol., 129, 1716-1722.
27. KORNHUBER, J., SCHULTZ, A., WILTFANG, J., MEINEKE, I., GLEITER, C.H., ZÖCHLING, R., BOISSL, K-W., LEBLHUBER, F. & RIEDERER, P. (1999). Persistence of haloperidol in human brain tissue. Am. J. Psychiatry, 156, 885-890.
28. KUO, A., GULBIS, J.M., ANTCLIFF, J.F., RAHMAN, T., LOWE, E.D., ZIMMER, J., CUTHBERTSON, J., ASHCROFT, F.M., EZAKI, T. & DOYLE, D.A. (2003). Crystal structure of the potassium channel KirBac1.1 in the closed state. Science, 300, 1922-1926.
29. + current: an external open channel blocker preventing fast inactivation. Biophys. J., 75, 2845-2857.
30. + channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat. Neurosci., 4, 507-512.
31. ATP channel-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 95, 10402-10406.
32. ATP channel kinetics in isolated membrane patches from rat ventricle. Biophys. J., 60, 1164-1177.
33. ATP channels is mediated by Kir6.2. Proc. Natl. Acad. Sci. U.S.A., 94, 11716-11720.
34. REDFERN, W.S., CARLSSON, L., DAVIS, A.S., LYNCH, W.G., MACKENZIE, I., PALETHORPE, S., SIEGL, P.K., STRANG, I., SULLIVAN, A.T., WALLIS, R., CAMM, A.J. & HAMMOND, T.G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
35. ATP channels containing SUR2A or SUR2B subunits to nucleotides and pinacidil. Mol. Pharmacol., 58, 1318-1325.
36. B receptors in isolated substantia nigra neurones. Pflügers. Arch., 416, 473-475.
37. SAH, D.W. & BEAN, B.P. (1994). Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists. Mol. Pharmacol., 45, 84-92.
38. SEEMAN, P. & VAN TOL, H.H. (1994). Dopamine receptor pharmacology. Trends. Pharmacol. Sci., 15, 264-270.
39. i coupling specificity. J. Biol. Chem., 279, 1601-1606.
40. SHUBA, Y.M., DEGTIAR, V.E., OSIPENKO, V.N., NAIDENOV, V.G. & WOOSLEY, R.L. (2001. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem. Pharmacol., 62, 41-49.
41. SUESSBRICH, H., SCHONHERR, R., HEINEMANN, S.H., ATTALI, B., LANG, F. & BUSCH, A.E. (1997). The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br. J. Pharmacol., 120, 968-974.
42. + channels in the absence of the sulphonylurea receptor. Nature, 387, 179-183.
43. WIRSHING, D.A., BOYD, J.A., MENG, L.R., BALLON, J.S., MARDER, S.R. & WIRSHING, W.C. (2002). The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry, 63, 856-865.
44. ATP channels. Neuron, 22, 537-548.
45. ZHOU, Y., MORAIS-CABRAL, J.H., KAUFMAN, A. & MACKINNON, R. (2001). Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 resolution. Nature, 414, 43-48.